Article
Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.
International journal of hematology - 1 Dec 2024
Kirito Keita, Sugimoto Yuka, Gotoh Akihiko, Takenaka Katsuto, Ichii Michiko, Inano Tadaaki, Shirane Shuichi, Ito Masafumi, Zagrijtschuk Oleh, Qin Albert, Kawase Hiroaki, Sato Toshiaki, Komatsu Norio, Shimoda Kazuya
Abstract excerpt
Ropeginterferon alfa-2b (ropegIFN), a new-generation interferon-based agent, has been approved in Japan for patients with polycythemia vera (PV) who are ineligible for or respond inadequately to conventional treatment. However, long-term outcomes with ropegIFN in Japanese patients have not been reported. This extension of a phase 2 study of ropegIFN in Japanese patients with PV aimed to determine its long-term...
Topics
Join the communities discussing this publication.